Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06719518 · ClinicalTrials.gov registry record
Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device
A clinical trial of Blood Pressure, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT06719518: Recruiting study of Blood Pressure, sponsored by The University of Texas Health Science Center, Houston.
NCT06719518 is a study of Blood Pressure that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 40 participants, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06719518, a study of Blood Pressure, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to calibrate the ViTrack™ arterial pressure waveform against intra-arterial pressure (IAP) in dynamic clinical settings and to assess the optimized ViTrack™ design to measure and continuously track blood pressure over a wide, clinically-relevant pressure range.
Primary Outcome
255 time points compared across continuous blood pressure (mmHg)
Conditions Studied
Interventions
- DEVICE ViTrack device
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2026-07-31 |
What NCT06719518 shows while recruiting
NCT06719518 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which ViTrack device is the first listed.
NCT06719518 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06719518 about?
NCT06719518 is a clinical study titled "Performance Evaluation of the ViTrack Continuous Non-invasive Blood Pressure Measurement Device". The purpose of this study is to calibrate the ViTrack™ arterial pressure waveform against intra-arterial pressure (IAP) in dynamic clinical settings and to assess the optimized ViTrack™ design to measure and continuously track blood pressure over a wide, clinically-relevant pressure range.
What is the current status of trial NCT06719518?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-12-17. Estimated completion is 2026-07-31.
What conditions does trial NCT06719518 study?
This clinical trial studies the following conditions: Blood Pressure.
What interventions are being tested in trial NCT06719518?
The interventions under investigation include: ViTrack device (DEVICE).
Who is sponsoring clinical trial NCT06719518?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06719518 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06719518's enrollment target sits among peer trials
40 67th of 101 higher than 30 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
RECRUITING
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
VicorderCS NIBP Validation Study to Review The Ability to Capture Blood Pressure Measurements
RECRUITING
-
The GUARDIAN Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI